TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06481696

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol-based multivitamin supplement
Description: Natural polyphenol and vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Supplementation with folic acid at the standard dosage of 0.4 mg/die

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: In vitro fertilization/IntraCytoplasmic Sperm Injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: In vitro fertilization/IntraCytoplasmic Sperm Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Description: Controlled Ovarian Stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Description: Controlled Ovarian Stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix Acetate 0.5 MG/ML [Fyremadel]
Description: GnRH Antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix Acetate 0.5 MG/ML [Fyremadel]
Description: GnRH Antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously
Description: For the induction of oocyte maturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously
Description: For the induction of oocyte maturation
Study: NCT06775249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICE Mindfulness Program
Description: The ICE Mindfulness Program is a tailored, self-paced intervention designed for crew members in isolated and confined environments. It includes a three-week pre-departure online course with videos, audio, and cognitive exercises promoting mindfulness, flexibility, and creativity, requiring 15-30 minutes daily. Delivered via email, it blends elements from Mindfulness-Based Stress Reduction and the Langerian approach. Participants receive new content daily, focusing on stress reduction and adaptation in extreme settings. Pre-departure, the PI leads a 1.5-hour interactive session with group meditation. During the mission, bi-weekly booster sessions are conducted by the ESA MD, supplemented by ongoing access to training materials. Exercises include meditations, mindful discussions, and cognitive tasks, with flexibility to fit participant schedules. The program will be available in Italian, French, and English.
Study: NCT05116163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individuation Intervention plus implicit bias educational modules
Description: Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit bias educational modules
Description: Providers in the comparator arm will be given the same implicit bias educational modules to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implicit bias educational modules
Description: Providers in the comparator arm will be given the same implicit bias educational modules to complete.
Study: NCT05657119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI FSN - Lethal Means Reduction
Description: Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~* Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~* Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scripted FSN - Lethal Means Reduction
Description: Scripted lethal means reduction, firearm storage supplies, tailored text messages~* Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~* Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Firearm Safety Intervention - General Firearm Safety
Description: General information on gun safety, firearm storage supplies, tailored text messages~* Participate in a 10-minute scripted conversation about safe gun storage practice~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~* Receive 4 weeks of tailored text message reminders and encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Firearm Comparison - General Firearm Safety
Description: firearm storage supplies~\* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes
Study: NCT06526741

Intervention type: OTHER
Intervention: Longitudinal data collection
Description: This is an observational ambispective non-interventional registry collecting longitudinal real-world data only. There is no intervention.
Study: NCT06776367

Intervention type: OTHER
Intervention: Remote study participation and self-collection of specimens
Description: Participants in Group B will complete all study procedures remotely and will not physically visit any clinical research site. This will include telehealth (videoconference) visits with study personnel, self-collection of specimens, shipping of specimens using pre-labeled packaging, and completion of electronic diaries for data collection.

Intervention type: OTHER
Intervention: Traditional clinical trial participation with clinician-collected specimens
Description: Participants in Group A will attend study visits in person at a clinical research site and will have the majority of specimens collected by a clinician at the clinic. Group A participants will have some electronic diary usage.
Study: NCT06775938

Intervention type: OTHER
Intervention: resident exam
Description: Resident exam in May 2024.

Intervention type: OTHER
Intervention: resident exam
Description: Resident exam in May 2024.
Study: NCT06776003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Polymethyl-methacrylate (PMMA) cement is injected slowly into the vertebral body under constant bi-plane fluoroscopy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Vertebroplasty
Description: A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
Study: NCT05352763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simufilam
Description: simufilam 100 mg oral tablets
Study: NCT06326645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer Oral Product
Description: Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
Study: NCT04942106

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1 - Side-lying position followed by Supine position
Description: Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2 - Supine position followed by Side-lying position
Description: Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
Study: NCT05917405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
Study: NCT06142656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride tablet
Description: Metformin Hydrochloride 850 mg oral tablet
Study: NCT05917405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
Study: NCT06142656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin 50 MG
Description: Vildagliptin 50 MG oral tablets
Study: NCT06016933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spirulina gel
Description: Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SRP of all teeth
Description: Patients received oral hygiene instructions and SRP of all teeth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP of all teeth
Description: Patients received oral hygiene instructions and SRP of all teeth.
Study: NCT06495801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frendie PRO mobile application
Description: Frendie PRO mobile application offers employees an environment to manage their social relationships, organize leisure activities, and discuss personal or work-related matters.
Study: NCT06504108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium silicate-based sealer full Pulpotomy
Description: Using calcium silicate-based sealer as a capping agent after full pulpotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium silicate-based premixed putty full Pulpotomy
Description: Using calcium silicate-based premixed putty as a capping agent after full pulpotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Pulpotomy
Description: Using combination between calcium silicate-based sealer and calcium silicate-based premixed putty as a capping agent after full pulpotomy
Study: NCT06180564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-operative Infra-red thermography
Description: . In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
Study: NCT05820724

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET scan
Description: Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
Study: NCT06045585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of JY231 injection
Description: Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
Study: NCT06223022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive nurse-led telephone follow-up
Description: An intervention nurse call the patients regularly with predetermined intervals and give support
Study: NCT05820724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No PSMA PET
Description: Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- DCFPyl Injection
Description: DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
Study: NCT06373094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Dihydroxynaphthalate for Injection
Description: HHT201 will be injected into the muscle of gluteus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Dihydroxynaphthalate for Injection
Description: HHT201 will be injected into the muscle of gluteus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Dihydroxynaphthalate for Injection
Description: HHT201 will be injected into the muscle of gluteus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Dihydroxynaphthalate for Injection
Description: HHT201 will be injected into the muscle of gluteus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Dihydroxynaphthalate for Injection
Description: HHT201 will be injected into the muscle of gluteus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Dihydroxynaphthalate for Injection
Description: HHT201 will be injected into the muscle of gluteus.
Study: NCT05555589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
Study: NCT05616533

Intervention type: OTHER
Intervention: biopsy of tumor before treatment
Description: samples obtained from biopsy will be used in the zebrafish PDX model
Study: NCT05555589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
Study: NCT04759820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injecting Carbon Nanoparticles Suspension
Description: injecting Carbon Nanoparticles Suspension for lymph node detection
Study: NCT06483672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg, once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
Study: NCT04759820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injecting indocyanine green
Description: Injecting indocyanine green for lymph node detection
Study: NCT06543225

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04211714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG34217
Description: Single infusion
Study: NCT04851613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib/placebo
Description: afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Afuresertib/placebo
Description: afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
Study: NCT06581419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAP0971
Description: Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAP0971
Description: Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.
Study: NCT06170008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical microstructure-modified transparent silicone film sheet
Description: The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
Study: NCT04835766

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
Study: NCT06170008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical microstructure-modified transparent silicone film sheet
Description: The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Decellularized pig skin
Description: Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline gauze
Description: Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
Study: NCT05300308

Intervention type: OTHER
Intervention: usual care
Description: The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.